Noemi Puccio
Overview
Explore the profile of Noemi Puccio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
25
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bruzzese A, Martino E, Labanca C, Carida G, Mendicino F, Lucia E, et al.
Eur J Haematol
. 2025 Mar;
PMID: 40045912
The treatment landscape for relapsed or refractory acute lymphoblastic leukemia (RR ALL) has evolved significantly with the introduction of monoclonal antibodies such as blinatumomab and inotuzumab ozogamicin. These agents have...
2.
Labanca C, Vigna E, Martino E, Bruzzese A, Mendicino F, Carida G, et al.
Eur J Haematol
. 2025 Feb;
PMID: 39905676
Avatrombopag, a second-generation thrombopoietin receptor agonist (TPO-RA), represents a significant advancement in the treatment of chronic immune thrombocytopenic purpura (cITP) and a potential therapeutic option for other thrombocytopenic disorders. Approved...
3.
Labanca C, Martino E, Vigna E, Bruzzese A, Mendicino F, Lucia E, et al.
Eur J Haematol
. 2024 Nov;
114(3):386-399.
PMID: 39604778
Relapsed and refractory multiple myeloma (RRMM) remains a challenging condition despite advances in immunotherapies. Novel bispecific antibodies (BsAbs), including talquetamab, have shown promising efficacy in heavily pretreated patients, even those...
4.
Nano E, Reggiani F, Amaro A, Monti P, Colombo M, Bertola N, et al.
Noncoding RNA
. 2024 Sep;
10(5).
PMID: 39311383
A "watch and wait" strategy, delaying treatment until active disease manifests, is adopted for most CLL cases; however, prognostic models incorporating biomarkers have shown to be useful to predict treatment...
5.
Rossi T, Iorio E, Chirico M, Pisanu M, Amodio N, Gallo Cantafio M, et al.
Cell Prolif
. 2024 Sep;
57(12):e13730.
PMID: 39223828
Repressing BET proteins' function using bromodomain inhibitors (BETi) has been shown to elicit antitumor effects by regulating the transcription of genes downstream of BRD4. We previously showed that BETi promoted...
6.
Puccio N, Manzotti G, Mereu E, Torricelli F, Ronchetti D, Cumerlato M, et al.
Haematologica
. 2024 Jul;
109(12):4040-4055.
PMID: 38988264
Multiple myeloma (MM) is a dreadful disease, marked by the uncontrolled proliferation of clonal plasma cells within the bone marrow. It is characterized by a highly heterogeneous clinical and molecular...
7.
Tameni A, Mallia S, Manicardi V, Donati B, Torricelli F, Vitale E, et al.
Nucleic Acids Res
. 2024 Apr;
52(11):6171-6182.
PMID: 38597676
Chromatin modifiers are emerging as major determinants of many types of cancers, including Anaplastic Large Cell Lymphomas (ALCL), a family of highly heterogeneous T-cell lymphomas for which therapeutic options are...
8.
Favasuli V, Ronchetti D, Silvestris I, Puccio N, Fabbiano G, Traini V, et al.
Haematologica
. 2023 Jul;
109(1):231-244.
PMID: 37439377
DIS3 gene mutations occur in approximately 10% of patients with multiple myeloma (MM); furthermore, DIS3 expression can be affected by monosomy 13 and del(13q), found in roughly 40% of MM...
9.
Taiana E, Bandini C, Favasuli V, Ronchetti D, Silvestris I, Puccio N, et al.
Haematologica
. 2022 Sep;
108(1):219-233.
PMID: 36073514
Long non-coding RNA NEAT1 is the core structural component of the nuclear paraspeckle (PS) organelles and it has been found to be deregulated in multiple myeloma (MM) patients. Experimental evidence...
10.
Todoerti K, Ronchetti D, Puccio N, Silvestris I, Favasuli V, Amodio N, et al.
Cancers (Basel)
. 2021 Nov;
13(21).
PMID: 34771679
The biological impact of long non-coding RNAs (lncRNAs) in multiple myeloma (MM) is becoming an essential aspect of the investigation, which may contribute to understanding the disease's complex pathobiology, providing...